INTRODUCTION

Hypertension (HT), either as a primary cause or consequence of renal failure, is a major risk factor for high cardiovascular morbidity in uremic patients (1). HT in patients with end stage renal disease (ESRD) who are on hemodialysis (HD) is defined by either a systolic blood pressure (SBP) >150 mmHg or a diastolic blood pressure (DBP) >85 mmHg (2). HT occurs in 70-90% of HD patients, which is a substantially higher incidence than that in the general population (2-4). Several factors have been reported to be involved in the pathogenesis of HT in HD patients, most of which have been categorized according to whether they are volume-dependent or volume-independent based on the response to ultrafiltration, i.e., in terms of the response to volume removal and/or dietary sodium restriction. Volume-independent factors are characterized by increased activity of the rennin angiotensin aldosterone system (RAAS) and a limited rate of blood pressure (BP) reduction by volume reduction.

Theoretically, it should be relatively easy to control BP in most of HD patients by ensuring that patients maintain a target body weight during the HD treatment process, which is estimated by the dry weight. However, contrary to the aforementioned theory, most HD patients (~75%) require antihypertensive drugs to control BP (5). Many reasons have been proposed to explain this discrepancy between the theory and practice of regulating BP in HD patients. The reasons could be explained by the activation of volume-independent factors such as the RAAS, an overactive sympathetic nervous system, impaired vasodilatation, elevated erythropoietin (EPO), and secondary hyperparathyroidism.

The best way to avoid HT in HD patients would be to identify and remove those factors that play a dominant role. However, in clinical practice, it is difficult to determine which factors are responsible for HT, especially when the control of BP is intractable even in the face of substantial weight loss during HD. In addition, the responses of HD patients to antihypertensive therapy are highly variable.

Several causes seem to be involved in its difficulty to determine which single factor might cause HT in ESRD patients.
First, the multiple physiological factors that can cause HT may be distinct from the factors that maintain normal BP. Second, factors may interact with one another. For example, in some HT patients, there is a direct correlation between plasma renin activity and plasma concentrations of norepinephrine (NEP) (6). Third, hormones that directly regulate BP, such as angiotensin, also have stimulatory effects on the sympathetic nervous system, including enhancing sympathetic outflow and/or acting on stimulatory presynaptic receptors (7-12).

Collectively, the observations of associations among hyperparathyroidism, impairment of vitamin D metabolism, and overactivity of the sympathetic nervous system in ESRD patients suggest that the RAAS, the parathyroid hormone (PTH)-vitamin D-calcium axis, and sympathetic activity interact to make it difficult for ESRD patients to regulate their BP. We guess that the difficulty in the regulation of hypertension was affected by multiple factors, so we investigated which factors have effects on HT control according to the need of hypertensive drug.

The present study was carried out to analyze the associations between the degree of HT and various factors in ESRD patients who underwent HD.

**MATERIALS AND METHODS**

ESRD patients (n=114; 61 males, 53 females; age=53.1±13.0 yr, mean body mass=56.5±10.9 kg; mean height=163.6±9.1 cm) who had undergone HD periodically for at least 6 months (mean duration of HD=117±58.4 months) were enrolled in this study. All patients provided informed consent, and the study protocol was approved by the Ethics Committee of Soonchunhyang University Cheonan Hospital, Korea. All patients underwent HD for 12-15 hr per week using a dialyzer (polyamide membrane; Polyflux 6L, Gambro, Gambro Dialysatoren, Hechingen, Germany). The flow rate of the dialysate was fixed at 500 mL/min during each HD session. The blood flow rate was 250-300 mL/min. The variable-volume, single-pool urea kinetic model was used to for dialysis prescriptions and to monitor dietary protein intake (quantified as the normalized protein catabolic rate; nPCR).

The dose of HD was described as the fractional clearance of urea as a function of its distribution volume (Kt/V urea).

Among the 114 patients, there were 35 cases of diabetes mellitus (30.7%), 37 cases of HT (32.5%), 28 cases of chronic glomerulonephritis (24.6%), 4 cases of polycystic kidney disease (3.5%), 3 cases of renal tuberculosis (2.6%), and 7 cases with an unknown cause of ESRD (6.1%). There was no difference in the distribution of underlying disease among Group 1-4.

The blood pressure and heart rate were measured on the opposite arm of vascular access before and after HD, and the means of the results of last two weeks were used as data. The target SBP and DBP was 150 and 85 mmHg, respectively. All patients were placed on a low-sodium diet and interdialytic weight gain was required to be less than 3.0 kg. The target weight for each patient was established according to the maximum endurance of volume depletion by ultrafiltration.

In terms of the definition of dry weight as a point from which BP goes down, a large number of patients had not reached the point. In cases where the BP could not be regulated by employing a low-sodium diet to control body weight, antihypertensive drugs were prescribed as follows. The categories of antihypertensive drugs included β-blockers (atenolone, 50 mg/tablet), calcium channel blockers (spendil [felodipine], 5 mg/tablet; Norvasc [amlodipine camysylate], 5 mg/tablet), angiotensin-converting enzyme (ACE) inhibitors (enalapril, 10 mg/tablet), and angiotensin II receptor blockers (ARB) (Aprovel [irbesartan], 150 mg/tablet; Cozdar [losartan], 100 mg/tablet). Only one drug from each category was prescribed. The ACE inhibitor and the ARB were regarded as belonging to the same category. When BP could not be controlled even when the dose of the initially prescribed was doubled, an additional drug from another category was prescribed rather than increasing the dose of the drug prescribed initially. For patients who were prescribed with antihypertensive drugs from more than two categories, the drugs were prescribed without the vasodilator, minoxidil (5 mg/tablet). Minoxidil was prescribed only for cases in which BP remained elevated despite treatment with antihypertensive drugs from three categories. The first class of antihypertensive drug prescribed was either ARB (16 cases), calcium channel blockers (8 cases), the β-blocker (7 cases), or the ACE inhibitor (1 case). The number of the patients who used an antihypertensive drug (regardless of whether they used other category of antihypertensive drugs) was 61 for ARB, 58 for calcium channel blockers, 40 for the β-blocker, 12 for the vasodilator, and 7 for the ACE inhibitor.

Patients were classified into four groups according to the aforementioned drug treatment regimen to reflect the difficulty in the control of HT as follows: In Group 1, BP was within the normal range and no antihypertensive drugs were prescribed; in Group 2, control of BP required antihypertensive drugs from only one category; in Group 3, two or three categories of antihypertensive drug were required to control BP, but not minoxidil; and in Group 4, antihypertensive drugs from more than three categories were required to control BP, including minoxidil. The application of these criteria resulted in 22 cases (10 male and 12 female) in Group 1, 32 (14 male and 18 female) in Group 2, 46 (25 male and 21 female) in Group 3, and 14 (14 male and 2 female) in Group 4.

Blood samples were collected prior to HD (pre-HD) to measure CBC, blood chemistry, electrolytes, and concentrations of PTH, β2-microglobulin, renin, and aldosterone. Blood samples were collected from the antecubital vein contralateral to the site at which the vascular access was gained for HD. Samples were collected immediately prior to the initiation of HD and 10 min after the end of the HD ses-
sion to measure pre- and post-HD concentrations of renin, aldosterone, epinephrine (EP), and NEP, respectively. All samples were stored at -70°C until analysis. Commercially available radioimmunoassay kits were used to measure plasma concentrations of renin (Renin Riaebad; Dainabot, Tokyo, Japan), aldosterone (Immunotech SA, Marseille, France), EP and NEP (IBL, Hamburg, Germany), intact PTH (iPTH) (PTH-120 MIN IRMA; BioSource Europe SA, Belgium), and β2-microglobulin (β2-microglobulin radioimmunoassay kit; Abbott Laboratories, Chicago, IL, U.S.A.).

Statistical analyses were performed with SPSS for Windows (version 12.0; SPSS, Chicago, IL, U.S.A.). The duration of HD, and plasma concentrations of EPO, β2-microglobulin, iPTH, aldosterone, and NEP were presented as means ± SEM. The values of the remaining parameters were presented as means ± SD. To examine associations between these parameters and the severity of HT, we analyzed differences in the concentrations of iPTH, aldosterone, renin, EP, and NEP as well as the aldosterone/renin ratio among the groups of patients (Groups 1-4) using chi-squared tests (for categorical variables) and Kruskal-Wallis tests or ANOVA (analysis of variance). If the results were significant by ANOVA, we analyzed the difference among the groups based on Turkey’s multiple comparison test.

RESULTS

There were no significant associations between the following parameters and the degree of HT: age, duration of HD, dry weight, height, BMI, pre- and post-HD body weight, interdialytic weight gain, blood flow during HD, ultrafiltration during HD, nPCR, and the concentrations of Hb, Hct, EPO doses, albumin, calcium, phosphorus, total cholesterol, triglycerides, β2-microglobulin, and HCO3. However, the Kt/V urea was significantly lower (p<0.01) in Groups 3 (1.49 ± 0.29) and 4 (1.40 ± 0.23) compared to Group 2 (1.75 ± 0.40) (Table 1, Fig. 1). Pre- and post-HD SBP was significantly higher in Groups 3 and 4 compared to Groups 1 and 2 (p<0.01), but there was no such difference in DBP. The pre-HD (p<0.01) and post-HD (p<0.02) heart rate was significantly higher in Groups 3 and 4 than in Group 1 (Table 2). Changes in the concentrations of iPTH, aldosterone, renin, aldosterone, EP, and NEP were not associated with the degree of HT (data not shown). The concentration of iPTH was significantly higher in Group 4 than in Groups 1-3 (p<0.01; Table 3, Fig. 2). The pre-HD (p<0.01) and post-HD (p<0.01) aldosterone concentrations were significantly lower in Groups 3 and 4 compared to Groups 1 and 2. Neither pre- and post-HD renin concentrations nor pre- and post-HD aldosterone/

Table 1. Comparison of dialysis-related data among groups

|                | Group 1       | Group 2       | Group 3       | Group 4       | p*  |
|----------------|---------------|---------------|---------------|---------------|-----|
| Age (yr)       | 53.2±13.8     | 56.8±10.6     | 52.9±12.8     | 45.2±15.3     | 0.52 |
| HD duration    | 64.4±7.4      | 61.4±7.9      | 52.4±6.6      | 62.0±10.1     | 0.65 |
| Dry weight (kg)| 53.8±9.4      | 57.5±11.4     | 56.6±12.1     | 58.1±6.9      | 0.61 |
| Height (cm)    | 163.2±9.1     | 162.2±8.6     | 163.8±9.7     | 167.4±8.4     | 0.37 |
| BMI (kg/m²)    | 20.2±3.0      | 21.6±3.0      | 21.0±3.3      | 20.8±2.6      | 0.46 |
| Body weight (kg)| 56.9±10.0    | 60.2±12.1     | 60.4±13.0     | 62.1±6.5      | 0.57 |
| Pre-HD         | 54.4±9.5      | 57.6±11.6     | 57.7±12.7     | 58.6±6.3      | 0.63 |
| Weight gain (kg)| 2.8±1.1      | 2.7±1.0       | 2.8±0.8       | 3.3±1.0       | 0.32 |
| Blood flow     | 281.7±34.8    | 291.8±18.1    | 288.2±25.1    | 289.6±21.2    | 0.54 |
| Ultrafiltration| 3.3±0.8       | 3.2±0.9       | 3.3±0.9       | 3.6±1.0       | 0.40 |
| Kt/V urea      | 1.60±0.26     | 1.75±0.40     | 1.49±0.29     | 1.40±0.23     | <0.01|
| T              | a, b          | a             | b             | b             |     |
| NpCr           | 0.86±0.26     | 0.82±0.24     | 0.84±0.26     | 0.75±0.14     | 0.62 |

*pStatistical significance was tested by one-way analysis of variances among groups; \( \dagger \) The same letters indicate a difference not significant between groups based on Turkey’s multiple comparison test.

HD, hemodialysis; BMI, body mass index; Kt/V urea, the fractional clearance of urea as a function of its distribution volume.
The Factors of Intractable Hypertension in Hemodialysis Patients

Table 2. Comparison of blood pressure and heart rate among groups

|                     | Group 1       | Group 2       | Group 3       | Group 4       | \(p^*\) |
|---------------------|---------------|---------------|---------------|---------------|---------|
| Systolic blood pressure (mmHg) |               |               |               |               |         |
| Pre-HD T'           | 126.8±22.8    | 136.6±17.0    | 143.1±19.5    | 149.3±18.2    | <0.01   |
| Post-HD T'          | 124.5±19.2    | 129.1±16.3    | 140.9±19.4    | 140.7±18.6    | <0.01   |
| Diastolic blood pressure (mmHg) |           |               |               |               |         |
| Pre-HD T'           | 76.8±9.4      | 78.1±8.2      | 80.2±7.5      | 80.7±10.7     | 0.36    |
| Heart rate (beats/min) |               |               |               |               |         |
| Pre-HD T'           | 50.5±16.3     | 60.0±15.0     | 64.2±16.7     | 68.6±14.6     | <0.01   |

*Statistical significance was tested by one-way analysis of variances among groups; The same letters indicate a difference not significant between groups based on Turkey's multiple comparison test.

Table 3. Comparison of concentrations of intact parathyroid hormone (PTH), renin, aldosterone, epinephrine, and norepinephrine among groups

|                     | Group 1       | Group 2       | Group 3       | Group 4       | \(p^*\) |
|---------------------|---------------|---------------|---------------|---------------|---------|
| PTH T'              | 69.9±16.3     | 74.3±12.6     | 88.5±16.9     | 126.8±34.9    | <0.01   |
| Aldosterone         |               |               |               |               |         |
| Pre-HD T'           | 418.0±130.6   | 272.6±84.9    | 67.1±7.4      | 91.6±18.5     | <0.01   |
| Post-HD T'          | 333.5±115.6   | 289.5±89.6    | 62.9±9.0      | 92.9±23.8     | <0.01   |
| Renin               |               |               |               |               |         |
| Pre-HD              | 2.40±0.50     | 5.52±1.12     | 4.00±0.78     | 3.31±1.25     | 0.15    |
| Post-HD             | 4.34±0.83     | 8.51±1.64     | 5.56±1.09     | 4.44±2.20     | 0.15    |
| Aldosterone/renin ratio |         |               |               |               |         |
| Pre-HD              | 209.5±46.7    | 93.4±28.7     | 120.9±44.7    | 96.8±32.8     | 0.29    |
| Post-HD             | 96.7±28.2     | 39.5±7.1      | 50.2±14.6     | 61.3±16.8     | 0.13    |
| Epinephrine         |               |               |               |               |         |
| Pre-HD              | 39.9±4.9      | 41.5±2.6      | 43.0±3.4      | 44.5±4.5      | 0.91    |
| Post-HD             | 43.5±4.6      | 32.9±1.9      | 34.5±3.2      | 33.7±2.4      | 0.16    |
| Norepinephrine      |               |               |               |               |         |
| Pre-HD T'           | 188.6±32.8    | 281.4±35.5    | 225.3±28.9    | 366.4±66.7    | <0.05   |
| Post-HD             | 161.5±32.5    | 149.8±26.1    | 136.9±19.5    | 226.9±60.8    | 0.31    |

*Statistical significance was tested by one-way analysis of variances among groups; The same letters indicate a difference not significant between groups based on Turkey's multiple comparison test.

The pre- and post-HD EP concentration was 39.9±4.9 vs. 43.5±4.6 in Group 1, 41.5±2.6 vs. 32.9±1.9 in Group 2, 43.0±3.4 vs. 34.5±3.2 in Group 3, and 44.5±4.5 vs. 33.7±2.4 in Group 4, \(p=0.91\) for comparison of pre-HD EPO concentration among Groups 1-4; \(p=0.16\) for post-HD EPO concentration). The pre-HD NEP concentration was significantly higher in Group 4 than in Groups 1 and 3 \(p<0.05\), but was not significantly different in Group 2 (Table 3, Fig. 3). There was a significant correlation between pre- and post-HD NEP concentrations \(p<0.01\), but there was no correlation between pre-HD NEP concentrations and any of renin, aldosterone, and PTH concentrations.

Neither the pre- nor post-HD renin activity was significantly different between patients who did and those who did not use the ACE inhibitors, ARB, the \(\beta\)-blocker, calcium channel blockers, and minoxidil. However, both pre- and post-HD aldosterone concentrations were significantly lower in patients who used ARB compared to those who did not \(p<0.01\). Similarly, pre-HD aldosterone concentrations were significantly lower in patients who used the calcium channel blockers compared to those who did not \(p<0.01\); Table 4). Post-HD EP concentrations were significantly higher in patients who did not use minoxidil compared to those who did use this drug.
NEP concentrations were significantly lower in the patients who used the β-blocker compared to those who did not (p < 0.05). Pre- and post-HD NEP concentrations were significantly higher in patients who used minoxidil compared to those who did not (p < 0.05; Table 4).

**DISCUSSION**

In the present study, the degree of intractability of BP control in HD patients was associated with pre- and post-HD SBP, heart rate, Kt/V urea, pre- and post-HD aldosterone concentrations, and pre-HD NEP concentrations. Of course,

**Table 4.** Effects of antihypertensive drugs on the concentrations of renin, aldosterone, epinephrine, and norepinephrine

| Drug                  | ACEI       | ARB       | Beta-blocker | CCB       | Minoxidil |
|-----------------------|------------|-----------|--------------|-----------|-----------|
| **Renin**             |            |           |              |           |           |
| Pre-HD Absence        | 3.7 ± 0.5  | 3.0 ± 0.7 | 4.3 ± 0.7    | 3.6 ± 0.7 | 4.0 ± 0.5 |
| Pre-HD Presence       | 5.3 ± 1.6  | 4.5 ± 0.6 | 3.5 ± 0.7    | 4.2 ± 0.6 | 3.8 ± 1.0 |
| Post-HD Absence       | 5.9 ± 0.8  | 5.2 ± 1.1 | 6.4 ± 0.9    | 6.1 ± 1.0 | 6.1 ± 0.8 |
| Post-HD Presence      | 6.5 ± 2.1  | 6.4 ± 0.9 | 5.3 ± 1.1    | 5.9 ± 1.0 | 5.3 ± 1.6 |
| **Aldosterone**       |            |           |              |           |           |
| Pre-HD Absence        | 197.9 ± 39.0 | 347.8 ± 91.0 | 246.2 ± 54.8 | 307.4 ± 78.7 | 20.5 ± 42.6 |
| Pre-HD Presence       | 206.4 ± 129.1 | 128.9 ± 33.0 | 130.1 ± 46.3 | 130.9 ± 34.8 | 176.4 ± 84.8 |
| Post-HD Absence       | 185.2 ± 38.5 | 316.4 ± 91.7 | 229.8 ± 54.3 | 262.3 ± 69.0 | 194.4 ± 42.0 |
| Post-HD Presence      | 181.7 ± 104.5 | 122.6 ± 28.4 | 118.8 ± 38.1 | 135.8 ± 38.7 | 150.1 ± 69.0 |
| **Epinephrine**       |            |           |              |           |           |
| Pre-HD Absence        | 43.0 ± 2.1 | 43.9 ± 3.7 | 39.7 ± 2.3   | 41.6 ± 3.1 | 41.8 ± 2.3 |
| Pre-HD Presence       | 36.5 ± 4.5 | 41.3 ± 2.2 | 45.8 ± 21.0  | 42.5 ± 2.4 | 43.4 ± 2.9 |
| Post-HD Absence       | 36.8 ± 1.9 | 40.1 ± 3.6 | 36.9 ± 19.4  | 39.2 ± 2.9 | 36.6 ± 2.1 |
| Post-HD Presence      | 29.7 ± 2.8 | 33.8 ± 1.8 | 34.3 ± 15.2  | 33.7 ± 2.1 | 32.9 ± 1.5 |
| **Norepinephrine**    |            |           |              |           |           |
| Pre-HD Absence        | 255.3 ± 19.9 | 239.3 ± 33.4 | 216.6 ± 21.9^* | 236.3 ± 28.4 | 224.2 ± 19.3 |
| Pre-HD Presence       | 209.7 ± 47.9 | 254.0 ± 22.1 | 298.1 ± 30.9 | 257.5 ± 24.1 | 343.8 ± 44.4 |
| Post-HD Absence       | 154.9 ± 15.1 | 144.7 ± 20.6 | 142.2 ± 16.2^* | 143.9 ± 22.1 | 140.1 ± 13.9^* |
| Post-HD Presence      | 162.9 ± 45.8 | 161.2 ± 18.9 | 176.3 ± 26.4 | 163.9 ± 19.0 | 215.2 ± 42.6 |
| **Aldosterone/renin ratio** |            |           |              |           |           |
| Pre-HD Absence        | 139.3 ± 25.4 | 176.0 ± 33.0 | 143.8 ± 31.1 | 161.3 ± 32.6 | 137.3 ± 27.3 |
| Pre-HD Presence       | 69.7 ± 25.9 | 106.5 ± 28.6 | 107.7 ± 30.2 | 109.2 ± 29.7 | 99.2 ± 25.5 |
| Post-HD Absence       | 59.0 ± 9.9  | 87.0 ± 20.3^* | 57.4 ± 11.2  | 69.3 ± 16.1 | 55.9 ± 9.5 |
| Post-HD Presence      | 54.4 ± 17.2 | 44.7 ± 8.3  | 59.8 ± 14.4  | 51.3 ± 10.1 | 67.6 ± 22.4 |

* ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

Because drugs were prescribed after the commencement of HD, the pre- and post-HD values correspond to the values of the parameters in the absence and presence of each drug. * p<0.05; † p<0.01.
the associations between the aforementioned parameters and
the intractability of BP control do not necessarily mean these
factors were the cause of HT in these patients. SBP was higher
in those patients who required a greater number of different
antihypertensive drugs to control BP; this finding implies
that abnormally elevated BP was not controlled completely
in the HT patients in the present study.

There was no association between the degree of HT and
parameters such as body weight, interdialytic weight gain,
BMI, or amount of ultrafiltration during HD. To control the
HT of HD, first the patients should reach the target weight,
and if HT is not well controlled, the other factors should be
searched.

The value of Kt/V urea was significantly lower in Group
3 and 4 than Group 2 (Fig. 1). It suggests that the adequacy
of HD is an important factor to control HT. Interestingly,
aldosterone concentrations were lower in Groups 3 and 4
than in Groups 1 and 2, and aldosterone concentrations were
lower in patients who were treated with ARB and/or calcium
channel blockers. This result suggests that aldosterone could
be suppressed by hypertensive drugs in uncontrolled hyper-
tensive HD patients. HD, itself, seemed to have no effect on
the variation of renin and aldosterone because there was no
difference before and after HD. In the present study, NEP
concentrations were significantly higher in Group 4 than in
Groups 1 and 3 (Fig. 3), but there was no significant differ-
ence in the post-HD concentrations of NEP among the
groups. By contrast, there was a substantial individual vari-
atation in the changes in NEP concentrations before and after
HD, and there was no correlation between changes in NEP
concentrations and the degree of intractability of BP con-
trol. This suggests that NEP may be involved partly in HT
in HD patients.

We cannot explain why the apparent association between
plasma NEP concentrations and the degree of HT that was
observed prior to HD was no longer apparent after HD. How-
ever, it is worth noting that the process of HD can either
stimulate or suppress sympathetic activity. Some reports
showed that the plasma volume decreases during HD, which
can lead to an increase in plasma catecholamine concentra-
tions and in contrast, catecholamines are small molecules that
might be dialyzed and removed during HD (13–15). The
role of sympathetic activity on HT in hemodialysis was con-
troversial, but it seems to be that sympathetic activity is
individually involved in HT of HD patients. Minoxidil is
direct vasodilator. It induces a more marked activation of
adrenergic drive. However, our data (Table 4) showed that
the patients prescribed with minoxidill had a the higher
concentration of EP and a lower concentration of NEP at
post-HD. The reasons might be that the patients on minox-
idil had other drugs including β-blocker.

Interaction between renin and the hormones that regulate
calcium metabolism has been proposed to explain calcium-
induced vasoconstriction and sodium-sensitivity in HT pa-
tients (16). Raine and co-workers (17) reported higher intra-
cellular calcium concentrations within the platelets of ESRD
patients with elevated plasma concentrations of PTH com-
pared to patients with normal plasma concentrations of PTH;
moreover, they reported significant correlations between PTH
concentrations, platelet calcium concentrations, and mean
arterial BP. Similarly, hypercalcemia induced a greater increase
in BP in rats with ESRD than in normal rats (18). Such vas-
cular hyperresponsiveness can be reversed by parathyroidec-
tomy, which suggests that PTH plays an important role in
hypercalcemia-induced HT. In agreement with a previous
report, the intact PTH concentration in the present study was
significantly higher in Group 4 than in Groups 1-3,
which suggests that PTH is one of the factors that is involved
in the inability of ESRD patients to regulate BP effectively.

Previous reports indicated that the incidence of HT in EPO-
treated HD patients was 10-12% (19, 20). An increase in
total peripheral resistance is the primary cause of the increase
in BP in ESRD patients, while increased blood viscosity and
reversal of hypoxic vasodilation (21) have often been cited as
the main causes of the effects of EPO on total peripheral
resistance and BP (22-24). In the present study, we found no
significant difference in either the EPO dose or Hct and/or
Hb concentrations among the various groups. We thought
that EPO-induced hypertension could be controlled by hyper-
tensive drug, but further investigations are needed to prove
this.

Our study design had several limitations. First, we did not
examine all of the factors that have been implicated in the
development of HT in ESRD patients, such as arginine vaso-
pressin (25, 26), endothelial factors (27, 28), and natriuretic
peptides (29, 30). However, the aim of this study was not to
evaluate all the factors that are involved in HT, but rather
to elucidate which factor(s) may be responsible for HT in
ESRD patients. Second, antihypertensive drugs may stimu-
late the RAAS, sympathetic activity, and PTH. To reduce
such nonspecific effects, we evaluated parameters in patients
who were grouped based on their use of antihypertensive
drugs. Both pre- and post-HD aldosterone concentrations
were significantly lower in patients who used ARB, and pre-
HD aldosterone concentrations were significantly lower in
the patients who used calcium channel blockers. Because
aldosterone concentrations appeared to be influenced by the
antihypertensive drugs, this was not considered as a factor
that might be involved in HT. Third, our classification of
patients according to their use of antihypertensive drugs
does not mean that those factors that appeared to be associ-
ated with the degree of HT are necessarily the cause of HT.
Nevertheless, in practice, these factors should be addressed
as the first step in controlling HT in ESRD patients who are
undergoing HD.

In conclusion, we found that a low Kt/V urea, hyperpara-
thyroidism, and increased plasma NEP concentrations, rather
than traditional causes of HT, could be associated with the
intractability of BP control in ESRD patients who underwent HD.

REFERENCES

1. Acosta JH. Hypertension in chronic renal disease. Kidney Int 1982; 22: 702-12.
2. Agarwal R, Nissenson AR, Battel D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-7.
3. Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002; 39: 227-44.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
5. Mangiapane ML, Brody MJ. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-8.
6. Esler M, Julius S, Zewifler A, Randall O, Harburg E, Gardiner H, DeQuattro V. Mild high-renin essential hypertension: Neurogenic human hypertension? N Engl J Med 1977; 296: 405-11.
7. Fink GD, Bruner CA, Mangiapane ML. Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension 1987; 9: 355-61.
8. Mangiapane ML, Brody MJ. Vasoconstrictor and vasodilator sites within anteroventral third ventricle region. Am J Physiol 1987; 253: 827-31.
9. Bruner CA, Mangiapane ML, Fink GD, Webb RC. Area postrema ablation and vascular reactivity in deoxycorticosterone-salt-treated rats. Hypertension 1988; 11: 668-73.
10. Zimmerman BG. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci 1981; 60: 343-8.
11. Zimlichman R, Goldstein DS, Zimlichman S, Stull R, Keiser HR. Angiotensin II increases cytosolic calcium and stimulates catecholamine release in cultured bovine adrenomedullary cells. Cell Calcium 1987; 8: 315-25.
12. Tevetor SC, Gavvas H, Tiffi CP, Bernard DB, Idelson B, Brunner HR. Norepinephrine and rennin activity in chronic renal failure. Evidence for interacting roles in hemodialysis chronic renal failure. Evidence for interacting roles in hemodialysis hypertension. Hypertension 1981; 3: 294-9.
13. Balduzzi CA, Ernst W, Frei U, Koch KM. Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 1982; 31: 324-32.
14. Zucchieli P, Catizone L, Esposito ED, Fusaroli M, Ligabue A, Zuccala A. Influence of ultrafiltration on plasma renin activity and adrenergic system. Nephron 1978; 21: 317-24.
15. Cuche JL, Principe J, Selz F, Ruget G, Baglin A. Plasma free, sulfo- and glucaro-conjugated catecholamines in uremic patients. Kidney Int 1986; 30: 566-72.
16. Rentnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 1991; 14: 505-20.
17. Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS, Ledingham JG. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700-5.
18. Iseki K, Massy SG, Campese VM. Effects of hypercalcemia and PTH on blood pressure in normal and renal-failure rats. Am J Physiol 1986; 250: 924-9.
19. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-33.
20. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wierneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
21. Zoccali C, Ciccarelli M, Mallamaci F, Maggioni Q, Stornello M, Valvo E, Scapellato L. The role of endogenous opioids in the baroreflex dysfunction of dialysis patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 190-4.
22. Waston AJ, Di Pette D. Baroreflex sensitivity and pressor response in a rat model of uremia. Clin Sci 1985; 69: 637-40.
23. Teranishi Y, Sugino H, Ozono R, Ishioka N, Kumaizaki T, Tsuru H. Contribution of endogenous vasopressin to regional hemodynamics in borderline-hypertensive Hiroshima rats. Hypertens Res 2002; 25: 241-8.
24. Kario K, Mitsushashi T, Shimada K. Neurohumoral characteristics of older hypertensive patients with abnormal nocturnal blood pressure dipping. Am J Hypertens 2002; 15: 531-7.
25. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005; 23: 1831-7.